<DOC>
	<DOCNO>NCT00049179</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody gemtuzumab ozogamicin locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy cytarabine use different way stop cancer cell divide stop grow die . Combining gemtuzumab ozogamicin cytarabine may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine gemtuzumab ozogamicin cytarabine treat patient relapse acute myeloid leukemia .</brief_summary>
	<brief_title>S0117 Gemtuzumab Ozogamicin Plus Cytarabine Treating Patients With Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety efficacy gemtuzumab ozogamicin cytarabine patient relapse acute myeloid leukemia . - Determine frequency severity toxic effect regimen CD33-positive patient . - Determine , preliminarily , prognostic significance drug resistance phenotype , cytogenetics , molecular genetic characteristic patient treat regimen . OUTLINE : This multicenter study . - Induction : Patients receive gemtuzumab ozogamicin IV least 2 hour day 1 8 cytarabine IV continuously day 1-7 . - Consolidation : Beginning day 28 75 , patient achieve A1 bone marrow , B1 peripheral blood , C1 extramedullary disease status receive one course gemtuzumab ozogamicin cisplatin induction chemotherapy . Patients follow every 3 month 1 year , every 6 month 1 year , annually 3 year . PROJECTED ACCRUAL : A total 30-55 patient accrue study within 10-28 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute myeloid leukemia ( AML ) FAB M12 M47 No blastic transformation chronic myelogenous leukemia In first relapse prior complete response Patients relapse autologous allogeneic bone marrow peripheral blood stem cell transplantation eligible CD33 positive Prior myelodysplastic syndrome secondary AML allow Concurrent enrollment SWOG9007 ( cytogenetics protocol ) No clinical document CNS involvement AML PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic WBC great 30,000/mm^3 Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 1.5 time ULN Renal Not specify Cardiovascular No unstable cardiac arrhythmia No unstable angina Other HIV negative No malignancy within past 5 year except follow : Adequately treat basal cell squamous cell skin cancer Carcinoma situ cervix Adequately treat stage I II cancer currently complete remission Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No prior gemtuzumab ozogamicin AML Chemotherapy Prior hydroxyurea control high cell count allow Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 4 week since prior investigational agent recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
</DOC>